Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

Solid tumors, (NCT05395052)
Sponsors:
Fate Therapeutics 
Indicator
IND Enabling
Phase I
Phase II
Phase III
Multiple myeloma, MM (NCT05069935)
Sponsors:
Fate Therapeutics 
Indicator
IND Enabling
Phase I
Phase II
Phase III
Acute Myeloid Leukaemia, AML, (NCT04614636)
Sponsors:
Fate Therapeutics, Inc
Indicator
IND Enabling
Phase I
Phase II
Phase III
B-Cell Malignancies, NHL, (NCT04629729)
Sponsors:
Fate Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine